Navigation Links
Cure HIV Reaches Out to Foundation Community to Fund LiSAVIOR
Date:4/1/2008

HILTON HEAD ISLAND, S.C., April 1 /PRNewswire/ -- Dr. Roger Kenneth Hershline, PhD, MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to the funder community, including funding initiatives such as the Grand Challenges in Global Health initiative. The monies would be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World AIDS Day Conference in China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, pal
'/>"/>

SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
2. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
3. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
4. Genmab Reaches Milestones in Ofatumumab Collaboration
5. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
6. Fralex reaches 100th patient milestone in fibromyalgia study
7. Life Sciences Industry Reaches Crossroad Say Noted Pillsbury Attorneys
8. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record $58.8 Billion in 2007
9. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
10. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
11. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 14, 2014 In recent years, growing ... methods in product development and promotion has led to ... mistrust, fueled by concerns about the insidious impact of ... of spectacular fines to the world’s biggest pharmas for ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... Research Triangle Park, NC (PRWEB) January 14, 2014 ... diagnostic company focusing on ultra-sensitive POC diagnostic platforms and novel ... on their first round of financing netting a total of ... first outside equity capital in the company. This group of ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... a leading laboratory services company, recently announced its formation ... as GI Pathology, D-PATH Dermatopathology and OncoMetrix. ... CEO of Poplar Healthcare, "we felt it was imperative ... individual companies could belong, while still maintaining their unique ...
... Stem Cell Assurance, Inc. (SCLZ.PK) (the "Company") ... "BioRestorative Therapies, Inc."  The Company,s new web site address ... been advised by the Financial Industry Regulatory Authority (FINRA) ... will change from "SCLZ" to "BRTX" thirty days following ...
... Aug. 17, 2011 Planet Biopharmaceuticals, Inc. and its ... pharmaceutical company focused on providing products for allergy and ... Ph.D. has been named as the company,s Executive Chairman ... Officer on August 29, 2011. Odlaug will replace William ...
Cached Biology Technology:Poplar Healthcare Forms Parent Company, Launches New Web Site 2Stem Cell Assurance, Inc. Announces Change of Name to BioRestorative Therapies, Inc. 2Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman 2
(Date:4/17/2014)... , Respiratory syncytial virus (RSV) is a ... life-threating illness in very young and elderly populations. ... enters host cells through the fusion protein RSV ... interfering peptides that prevent bundle formation limit RSV ... susceptible to degradation. In this issue of the ...
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
Breaking Biology News(10 mins):JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6Fish consumption advisories fail to cover all types of contaminants 2
... an estimated 665,000 deaths, mostly among African children. Now, ... for the world,s most useful antimalarial drug, artemisinin, giving ... cost of the live-saving drug in the future. , ... been slow due to high production costs of artemisinin. ...
... a hormone released by the lining of the stomach that ... obesity -- in fact, a vaccine that lowers ghrelin levels ... treatment for obesity. However, many people eat as a ... its effectiveness as a treatment for obesity may be reduced. ...
... pose considerable health threats to humans, and the heavy metal ... are exposed to it through plant-derived foods such as grains ... can reduce the amount of Cd found in the food ... in the Cell Press journal Trends in Plant Science ...
Cached Biology News:IU chemist develops new synthesis of most useful, yet expensive, antimalarial drug 2Low ghrelin -- reducing appetite at the cost of increased stress? 2Studies shed light on how to reduce the amount of toxins in plant-derived foods 2
... for arraying proteins of interest with ... equipment. DiscoverLight Protein Array Kits allow ... cell lysate or antibody in a ... specially designed nitrocellulose membranes with a ...
... for Alkaline Phosphatase conjugates. The product ... both the enzyme and the antibody following ... product has been chemically engineered to increase ... shelf life, resistance to various shipping conditions ...
Request Info...
NovaScreen offers cell biology, cell culture and molecular biology services for companies who lack a cell culture facility....
Biology Products: